Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine + Fluoxetine in Treatment-Resistant Depression
NCT00035321Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2002
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Olanzapine + Fluoxetine, Olanzapine and Fluoxetine (3 arms). Primary endpoint: Montgomery-Asberg Depression Rating Scale Total Score Change at 8 weeks. Started Apr 2002; status: completed.
02
Drugs
olanzapinefluoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00035321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00035321.